Feeds:
Posts
Comments

Posts Tagged ‘LHRH agonist’

URO TODAY: Degarelix, a recently approved LHRH antagonist, has been shown to work more quickly in lowering serum testosterone levels, with acceptable safety and a mechanism that avoids the testosterone surges associated with LHRH agonist use. READ MORE>

Read Full Post »

JULY 27: URO TODAY: A combination approach to hormone and radiation treatment for men with localised but high risk prostate cancer works better than so-called mono-therapy, a new study has found. READ MORE>

Men treated with external beam radiotherapy and brachytherapy, short-course androgen suppression therapy with a luteinizing hormone-releasing hormone (LHRH) agonist plus an anti-androgen, have decreased prostate cancer-specific mortality compared with mono-therapy with an LHRH agonist, the researchers report.

NEW PROSTATE CANCER INFOLINK: Another study (of about 200 patients) in Japan found combined androgen blockade with an LHRH) agonist + bicalutamide 80 mg had a small, marginally significant overall survival benefit compared to an LHRH agonist + a placebo (ie, LHRH agonist monotherapy) at a median follow-up of 5.2 years. READ MORE>

Read Full Post »